Ruijian Pharmaceuticals Initiates World's First Clinical Trials of Chemically Induced Cell-Derived Extracellular Vesicle Product NouvSoma001

Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Comments pointing out any inaccuracies are welcome. This article is only an introduction to medical and health-related drugs and does not recommend treatment plans (if involved). This article does not constitute any investment advice.

Recently,Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, in collaboration with iRegene, has initiated the world's first clinical study of NouvSoma001, an extracellular vesicle product derived from chemically induced cells.After rigorous preliminary preparations, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, successfully launched the "Exploratory Clinical Study Evaluating the Safety and Efficacy of NouvSoma001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders (NMOSD)." The project successfully passed the review by the Ethics Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, obtained ethical approval, and recently held a successful clinical trial initiation meeting.

This project is led by Professor Wang Wei, Standing Committee Member of the Party Committee, Executive Vice President of Huazhong University of Science and Technology, and Secretary of the Party Committee of Tongji Hospital, in collaboration with Professor Tian Daishi from the Department of Neurology. The study involves an open-label, placebo-controlled, single-center clinical investigation assessing the safety, tolerability, and efficacy of intrathecal injection of extracellular vesicles in patients with neuromyelitis optica spectrum disorders.

This clinical trial focuses on neuromyelitis optica spectrum disorder (NMOSD), an immune-mediated inflammatory demyelinating disease of the central nervous system. Due to the immune system attacking the optic nerves and spinal cord, NMOSD is clinically characterized by optic neuritis, longitudinally extensive transverse myelitis, area postrema syndrome, brainstem syndrome, diencephalic syndrome, and cerebral syndrome, ultimately leading to vision loss and paralysis. NMOSD can be treated with corticosteroids (e.g., methylprednisolone) and immunosuppressive drugs, but there is currently no cure. This project utilizes a chemically induced cell-derived extracellular vesicle product, NouvSoma001, for the treatment of neuromyelitis optica spectrum disorder (NMOSD).YesActive exploration of a novel therapy for this immune-mediated inflammatory demyelinating disease of the central nervous system.

Also launched synchronously this time is the "Exploratory Clinical Study Evaluating the Safety and Efficacy of NouvSoma001 Injection in the Treatment of Ischemic Stroke" conducted by the same research team. This project involves an open-label, placebo-controlled, single-center clinical study on ischemic stroke patients via intravenous injection to evaluate safety, tolerability, and efficacy respectively. Ischemic stroke refers to sudden neurological deficits caused by localized cerebral ischemia and permanent cerebral infarction (e.g., positive DWI findings). The research team has systematically and rigorously explored the mechanisms of NouvSoma001, a chemically induced cell-derived extracellular vesicle product, in ischemic stroke. Additionally, intravenous administration of extracellular vesicles has paved the way for exploring a safer novel treatment approach for ischemic stroke.

The teams participating in this clinical trial kick-off meeting include Professor Wang Wei, Professor Tian Daishi, Associate Professor Qin Chuan, Chief Physician Shang Ke, Deputy Chief Physician Xiao Jun from Tongji Hospital affiliated with Huazhong University of Science and Technology, as well as Dr. Cai Meng (CMO), Dr. Wei Jun (CEO), and Dr. Yan Ruorong (R&D Vice President) from iRegene. During the meeting, representatives thoroughly discussed the background, protocol, operational details, and risk contingency plans for this clinical trial. Leveraging the profound academic accumulation in neuroimmunology, superior clinical resources, and rigorous clinical trial systems of Professor Wang Wei, Professor Tian Daishi, and Associate Professor Qin Chuan's team from Tongji Hospital affiliated with Huazhong University of Science and Technology, the implementation of this project is ensured.

NouvSoma001 Injection is developed by iRegene Therapeutics Co., Ltd. (iRegene) using its existing mature technology platform,A fully self-developed extracellular vesicle product based on chemical induction. Systematic preclinical studies have preliminarily demonstrated the safety and efficacy of this product in primate models., which lays the foundation for the clinical application of this product and supports its clinical feasibility. These two investigator-initiated clinical trials also mark iRegene's official entry into the era of cell-derived products.

Source: iRegene